Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.
M. Tansey, S. Bozeat, Peter Ackerman et al.· Alzheimer's & Dementia· 0 citations
Alzheimer's disease neuropathologic change (ADNC) and limbic‐predominant age‐related transactive response DNA‐binding protein 43 kDa (TDP‐43) encephalopathy neuropathologic change (LATENC) are common in older adults, yet differences in brain morphometry patterns when one or both pathologies are present remain unclear.
Khalid Saifullah, A. Ridwan, Arnold M. Evia et al.· Alzheimer's & Dementia· 0 citations
It is suggested that brain iron may contribute to the clinical impact of CAA in older age and whether brain iron modulates the association of CAA with cognitive decline is investigated.
S. Agrawal, Maude Wagner, S. Leurgans et al.· Acta Neuropathologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.